Home › ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO
 

Keywords :   


ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

2015-06-02 03:40:01| Biotech - Topix.net

The biggest upside surprise from the American Society for Clinical Oncology meeting in Chicago, which ends Tuesday, probably came from , a beleaguered biotech that came back to life thanks to its antibody drug conjugate mirvetuximab soravtansine, or IMGN853. The drug's objective response rate - the percentage of tumors that shrank - was 53%, which induced several price-target increases and an upgrade to equal weight from Morgan Stanley.

Tags: drugs scrutiny surprises asco

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 3
29.06Tropical Storm Beryl Public Advisory Number 3
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 3
29.06Tropical Storm Beryl Forecast Advisory Number 3
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
More »